human protein array
The UniPEx protein array contains > 36,000 spots with > 14,000 distinct human antigens. The UniPEx protein expression library consists of 1 Array representing clones in 2 different modified vectors, expressed in 2 different E. coli strains.
In total, more than 100,000 sequenced clones from different protein expression libraries (human fetal brain, T-cells, lung and colon) were analyzed in depth for their coding potential.
After in-frame analysis, mostly clones with a confirmed in-frame ORF were selected and redundancy with respect to clones per gene was minimized (< 3 fold).
Find out more about protein classes, tissue expression & disease involvement in regard to our array content.
Protein Array Service
We support you in biomarker discovery and the determination of antibody specificity. With our
protein array analysis we offer full service around protein arrays.
Human fetal brain, CD4+ T-cells, lung and colon cDNA
Number of spots:
36,864 spots in total, 6,216 (16.9 %) controls, 30,648 protein-coding E. coli clones
Number of distinct antigens/genes:
14,240 different antigens which represent > 5,000 different genes
Controls & multiple determination:):
Controls are guiding spots, blanks & E. coli clones with empty vectors. Protein-coding E. coli clones are spotted at least in duplicate.
Mixture of partially de-and renaturated
Protein length & ORF:
1,484 different in-frame full-length proteins (10.4 % of spots in total); 9,132 in-frame protein isoform variants & peptides (64.1 % of spots in total); 3,624 neoantigens & frameshift peptides (25.4 % of spots
Tag (for detection and purification purposes):
Array matrix and size:
PVDF-membrane, 222mm x 222mm (approx. 8.7 inch x 8.7 inch)
1.100 € per array, bulk discount possible
We used the protein macroarrays to screen for protein-protein interaction (PPI) partners using fluorophore-labelled peptide baits. This enabled us to identify the histone lysine N-methyltransferase EHMT2/G9a as an interaction partner and functional modulator of trans-activation domains of transcription factors of the C/EBP family (1). We have further extended these PPI screens on UniPEx Arrays and to differentially post-translationally modified (PTM) peptides as baits. Thereby, we could not only measure large numbers of protein interactions on approximately one-third of the proteome simultaneously, but also explore a protein´s interactome depending on defined PTM states (2). An advantage of this approach using UniPEx protein/peptide libraries was the presence of large amounts of unmodified pray protein (expressed in E. coli) in combination with a defined duplicate spotting pattern, which enables quick exclusion of false-positive interactions.
1 Pless O, Kowenz-Leutz E, Knoblich M, Lausen J, Beyermann M, Walsh MJ & Leutz A.(2008), G9a-mediated Lysine Methylation Alters the Function of CCAAT/Enhancer-binding Protein-beta. The Journal of Biological Chemistry VOL. 283, NO. 39, pp. 26357–26363; DOI: 10.1074/jbc.M802132200.
2 Pless O, Kowenz-Leutz E, Dittmar G & Leutz A (2011), A differential proteome screening system for post-translational modification–dependent transcription factor interactions. Nature Protocols VOL.6 NO. 3; DOI: 10.1038/nprot.2011.303
Ole Pless, PhD
Fraunhofer IME Screening Port, Hamburg, Germany
To our experience, the protein arrays are super-informative and yield highly reproducible results specifically for biomarker discovery and validation. We have screened Testis, Fetal hEX1, UniPEx and hEXselect protein arrays to identify autologous antibodies specific to Small Cell Lung Cancer (SCLC), Non-small Cell Lung Cancer (NSLCL), Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Behcet’s disease and Neuromyelitis optica (NMO) in comparison with healthy controls. We were able to identify disease specific autologous antibodies and validate them via custom-made arrays. The nature and format of the protein arrays provided us the opportunity to develop a screening protocol by which we were able to generate signals in a broad dynamic range, obtain high signal/background and positive signal/negative signal ratios. Further, we could identify novel autologous antibodies which we will publish after validation with ELISA and Western blot.
Şükrü Atakan, Postdoctoral Researcher
Bilkent University, Turkey
Have a look at our publication list with more than 100 studies using engine protein arrays. Our arrays based on
the technique of Source Biosciences, imaGenes and RZPD.